2seventy bio, Inc. (TSVT) Financial Statements (2026 and earlier)

Company Profile

Business Address 60 BINNEY STREET
CAMBRIDGE, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments71,24474,958266,270265,057
Cash and cash equivalent71,24474,95871,032130,414
Short-term investments   195,238134,643
Receivables7,78113,41120,96016,995
Prepaid expense4,7217,36513,6529,512
Other undisclosed current assets103,510142,031  
Total current assets:187,256237,765300,882291,564
Noncurrent Assets
Operating lease, right-of-use asset204,391219,958240,885275,534
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization33,75958,15055,73534,913
Long-term investments and receivables   1,41497,124
Long-term investments   1,41497,124
Intangible asset, including goodwill, after accumulated amortization5,885(5,506)19,35821,948
Goodwill  (12,100)12,05612,056
Intangible asset, excluding goodwill, after accumulated amortization5,8856,5947,3029,892
Other undisclosed noncurrent assets48,21955,05938,39138,592
Total noncurrent assets:292,254327,661355,783468,111
TOTAL ASSETS:479,510565,426656,665759,675
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,89123,00238,80247,044
Employee-related liabilities✕✕✕✕24,655
Accounts payable1,0556,0287,2086,024
Accrued liabilities12,83616,97431,59416,365
Deferred revenue  15,4033,0005,000
Other undisclosed current liabilities26,20121,37437,99246,344
Total current liabilities:40,09259,77979,79498,388
Noncurrent Liabilities
Long-term debt and lease obligation:    272,446
Liabilities, other than long-term debt228,612250,347266,40527,884
Deferred revenue  3,9185,00025,762
Other liabilities1,2602,4162,3972,122
Operating lease, liability227,352244,013259,008272,446
Other undisclosed noncurrent liabilities    1,135
Total noncurrent liabilities:228,612250,347266,405301,465
Total liabilities:268,704310,126346,199399,853
Equity
Equity, attributable to parent210,806255,300310,466359,822
Common stock5542
Additional paid in capital779,176766,716606,986400,026
Accumulated other comprehensive income (loss)89(204)(2,877)(712)
Accumulated deficit(568,464)(511,217)(293,647)(39,494)
Total equity:210,806255,300310,466359,822
TOTAL LIABILITIES AND EQUITY:479,510565,426656,665759,675

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues37,862100,38791,49654,522
Cost of revenue(26,203)(16,453)(23,851)(8,727)
Cost of product and service sold  (2,099)(1,726)(2,517)
Gross profit:11,65983,93467,64545,795
Operating expenses(127,089)(321,542)(330,785)(359,743)
Operating loss:(115,430)(237,608)(263,140)(313,948)
Nonoperating income
(Other Nonoperating income)		4,3477,6256,05521,647
Loss from continuing operations before equity method investments, income taxes:(111,083)(229,983)(257,085)(292,301)
Other undisclosed income from continuing operations before income taxes53,83612,4132,93288
Loss from continuing operations:(57,247)(217,570)(254,153)(292,213)
Loss before gain (loss) on sale of properties:✕✕✕✕(292,213)
Net loss available to common stockholders, diluted:(57,247)(217,570)(254,153)(292,213)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(57,247)(217,570)(254,153)(292,213)
Other comprehensive income (loss)2932,673(2,165)(482)
Other undisclosed comprehensive income    
Comprehensive loss:(56,954)(214,897)(256,318)(292,695)
Other undisclosed comprehensive loss, net of tax, attributable to parent   (230)
Comprehensive loss, net of tax, attributable to parent:(56,954)(214,897)(256,318)(292,925)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: